-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Global rights and interests Insight database of LAG-3 monoclonal antibody Sym022 Global new drug moduleLAG-3 is the third immune checkpoint to achieve commercialization in the world after PD-1 and CTLA-4, and has been shown in PD-1 combination therapy Excellent curative effe.
Relatlimab + NivolumabAccording tothe global new drug data of the Insight database, there are currently 50 LAG3 antibody drug projects under development, of which 27 have entered the clinical development stage, including 18 monoclonal antibodies, 7 double antibodies, and 2 monoclonal antibody compoun.
Insight database global new drugsAt present, LAG3 antibody is mainly developed in the form of PD-1 combinati.
Merck's MK-4280A Regeneron / Sanofi's fianlimabInsight database has been approved by the PD-(L)1 monoclonal antibody among the companies, Hengrui , Innovent, Baiji, Henlius, Yuheng, Kel.
all have LAG-3 monoclonal antibody projects under resear.
Insight database global new drugsFrom the trend point of view, the application of LAG3 target projects began to burst out in 2019, and in 2021 A total of 15 projects have entered the clinical development stage, including 10 domestically produced and 5 import.
The research and development trend of domestic LAG3 projects comes from: Insight databaseproject progress (http://.
d.
cn/v5/home/)Innovent is the only company that has both monoclonal and dual-clinical antibodies in clinical tria.
LAG3 monoclonal antibody IBI110 has started Phase II clinical trials, and PD-L1/LAG3 dual-antibody IBI323 is in Phase I clinical pha.
The projects entering Phase II clinical trials also include 3 LAG3 mAbs: SHR-1802 of Hengrui Medicine, LBL-007 of Baiji/Vilizhibo, and DNV3 of Shimai Pharmaceutica.
LAG3 mAb in Phase II clinical trials in ChinaInsight database
Relatlimab + NivolumabAccording tothe global new drug data of the Insight database, there are currently 50 LAG3 antibody drug projects under development, of which 27 have entered the clinical development stage, including 18 monoclonal antibodies, 7 double antibodies, and 2 monoclonal antibody compoun.
Insight database global new drugsAt present, LAG3 antibody is mainly developed in the form of PD-1 combinati.
Merck's MK-4280A Regeneron / Sanofi's fianlimabInsight database has been approved by the PD-(L)1 monoclonal antibody among the companies, Hengrui , Innovent, Baiji, Henlius, Yuheng, Kel.
all have LAG-3 monoclonal antibody projects under resear.
Insight database global new drugsFrom the trend point of view, the application of LAG3 target projects began to burst out in 2019, and in 2021 A total of 15 projects have entered the clinical development stage, including 10 domestically produced and 5 import.
The research and development trend of domestic LAG3 projects comes from: Insight databaseproject progress (http://.
d.
cn/v5/home/)Innovent is the only company that has both monoclonal and dual-clinical antibodies in clinical tria.
LAG3 monoclonal antibody IBI110 has started Phase II clinical trials, and PD-L1/LAG3 dual-antibody IBI323 is in Phase I clinical pha.
The projects entering Phase II clinical trials also include 3 LAG3 mAbs: SHR-1802 of Hengrui Medicine, LBL-007 of Baiji/Vilizhibo, and DNV3 of Shimai Pharmaceutica.
LAG3 mAb in Phase II clinical trials in ChinaInsight database
